CY1122647T1 - Μεθοδος ανιχνευσης των pik3ca μεταλλαξεων σε ενα δειγμα - Google Patents
Μεθοδος ανιχνευσης των pik3ca μεταλλαξεων σε ενα δειγμαInfo
- Publication number
- CY1122647T1 CY1122647T1 CY20191101363T CY191101363T CY1122647T1 CY 1122647 T1 CY1122647 T1 CY 1122647T1 CY 20191101363 T CY20191101363 T CY 20191101363T CY 191101363 T CY191101363 T CY 191101363T CY 1122647 T1 CY1122647 T1 CY 1122647T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pik3ca
- mutations
- sequence
- pik3ca mutations
- serum
- Prior art date
Links
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 title abstract 6
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 title abstract 6
- 230000035772 mutation Effects 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 108020004414 DNA Proteins 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 239000000523 sample Substances 0.000 abstract 3
- 108700028369 Alleles Proteins 0.000 abstract 2
- 230000003321 amplification Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000005266 circulating tumour cell Anatomy 0.000 abstract 2
- 238000001514 detection method Methods 0.000 abstract 2
- 238000011880 melting curve analysis Methods 0.000 abstract 2
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 108700024394 Exon Proteins 0.000 abstract 1
- 238000007846 asymmetric PCR Methods 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- 102200085789 rs121913279 Human genes 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 238000002626 targeted therapy Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/186—Modifications characterised by incorporating a non-extendable or blocking moiety
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2527/00—Reactions demanding special reaction conditions
- C12Q2527/107—Temperature of melting, i.e. Tm
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462034231P | 2014-08-07 | 2014-08-07 | |
| PCT/GR2015/000036 WO2016020710A1 (en) | 2014-08-07 | 2015-07-28 | Method of determining pik3ca mutational status in a sample |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122647T1 true CY1122647T1 (el) | 2021-03-12 |
Family
ID=53938365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101363T CY1122647T1 (el) | 2014-08-07 | 2019-12-30 | Μεθοδος ανιχνευσης των pik3ca μεταλλαξεων σε ενα δειγμα |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11279979B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3198026B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6770957B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106715723B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2957396C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1122647T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3198026T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2764423T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20192353T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE047958T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL250392B (cg-RX-API-DMAC7.html) |
| LT (1) | LT3198026T (cg-RX-API-DMAC7.html) |
| PL (1) | PL3198026T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3198026T (cg-RX-API-DMAC7.html) |
| RS (1) | RS59710B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3198026T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT202000005T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016020710A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3023788T3 (da) | 2010-05-14 | 2020-04-27 | Massachusetts Gen Hospital | Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer |
| WO2015039024A1 (en) | 2013-09-16 | 2015-03-19 | Oregon Health & Science University | Bioabsorbable clips and applicator for tissue closure |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| CA2934073A1 (en) | 2013-12-20 | 2015-06-25 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| US9883866B2 (en) | 2014-11-03 | 2018-02-06 | Oregon Health & Science University | Clips and applicator for tissue closure |
| EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
| ES3049406T3 (en) * | 2014-12-19 | 2025-12-16 | Broad Inst Inc | Methods for profiling the t-cell-receptor repertoire |
| PE20180670A1 (es) | 2015-05-20 | 2018-04-19 | Broad Inst Inc | Neoantigenos compartidos |
| US10870891B2 (en) | 2017-01-05 | 2020-12-22 | Biodesix, Inc. | Diagnostic test system for specific, sensitive and reproducible detection of circulating nucleic acids in whole blood |
| EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| CN118370809A (zh) | 2017-04-03 | 2024-07-23 | 百欧恩泰美国公司 | 蛋白质抗原及其用途 |
| CN107287309A (zh) * | 2017-07-06 | 2017-10-24 | 罗保君 | 一种血液循环肿瘤dna点突变检测方法 |
| JP6603827B2 (ja) * | 2017-07-26 | 2019-11-06 | 積水メディカル株式会社 | 変異遺伝子検出方法 |
| CN109295175A (zh) * | 2017-09-08 | 2019-02-01 | 广州健天基因技术有限公司 | 用于检测人胃肠道间质瘤c-kit基因v559a突变的引物、检测方法及试剂盒 |
| CN109306374A (zh) * | 2017-09-08 | 2019-02-05 | 广州健天基因技术有限公司 | 用于检测人类pik3ca基因e545k突变的引物、检测方法及试剂盒 |
| JP7306618B2 (ja) * | 2017-09-26 | 2023-07-11 | 東ソー株式会社 | がんの転移形成能に関与する因子および前記因子を用いたがん患者の予後予測方法 |
| WO2019126186A1 (en) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
| CN107937490A (zh) * | 2018-01-15 | 2018-04-20 | 福建农林大学 | 一种非对称pcr的试纸条检测植物病原菌的方法及试剂盒 |
| WO2019155050A1 (en) * | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Method of predicting response to therapy by assessing tumor genetic heterogeneity |
| JP7534962B2 (ja) | 2018-06-19 | 2024-08-15 | ビオンテック ユーエス インコーポレイテッド | ネオ抗原およびその使用 |
| CN109666747A (zh) * | 2019-02-20 | 2019-04-23 | 天津脉络医学检验有限公司 | 一种引物探针组合物及其应用 |
| US11812966B2 (en) | 2020-04-24 | 2023-11-14 | NeuraMedica Inc. | Clips, appliers, and cartridges |
| CN113930500B (zh) * | 2020-07-13 | 2024-11-19 | 铭炽生物科技(上海)有限公司 | 人pik3ca基因突变的数字pcr检测方法及应用 |
| CN112951325B (zh) * | 2021-02-18 | 2023-04-21 | 北京吉因加医学检验实验室有限公司 | 一种用于癌症检测的探针组合的设计方法及其应用 |
| CN113063835B (zh) * | 2021-03-19 | 2022-08-02 | 中山大学 | 一种基于元素标记-电感耦合等离子体质谱检测策略的cfDNA分析方法及其应用 |
| WO2023025218A1 (zh) * | 2021-08-25 | 2023-03-02 | 南京金斯瑞生物科技有限公司 | 一种用于检测单碱基突变的引物组和基因芯片方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3296407T1 (sl) | 2004-03-02 | 2019-09-30 | The Johns Hopkins University | Mutacije gena PIK3CA pri rakih pri ljudeh |
| SG10201506658TA (en) * | 2007-02-26 | 2015-09-29 | Wayne John Cancer Inst | Utility of b-raf dna mutation in diagnosis and treatment of cancer |
| US8071338B2 (en) * | 2007-08-08 | 2011-12-06 | Roche Molecular Systems, Inc. | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity |
| GB2453173A (en) * | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| US20100041048A1 (en) * | 2008-07-31 | 2010-02-18 | The Johns Hopkins University | Circulating Mutant DNA to Assess Tumor Dynamics |
| CN101445832B (zh) * | 2008-12-23 | 2011-09-14 | 广州益善生物技术有限公司 | Pik3ca基因突变的检测探针、液相芯片及其检测方法 |
| CN102234685B (zh) * | 2010-04-23 | 2014-08-27 | 益善生物技术股份有限公司 | 一种pik3ca基因突变检测液相芯片 |
| WO2012075231A1 (en) * | 2010-12-03 | 2012-06-07 | Brandeis University | Methods and kits for detecting nucleic acid mutants in wild-type populations |
| CN102533958A (zh) | 2010-12-28 | 2012-07-04 | 苏州科贝生物技术有限公司 | 一种检测人pik3ca基因突变的方法和试剂盒 |
| EP2663652B1 (en) * | 2011-01-11 | 2018-11-14 | Roche Diagniostics GmbH | High resolution melting analysis as a prescreening tool |
| WO2012131092A2 (en) * | 2011-03-31 | 2012-10-04 | Signature Diagnostics Ag | Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages |
| CN103635593B (zh) * | 2011-05-04 | 2018-03-20 | 生物概念股份有限公司 | 用于检测核酸序列变体的方法 |
| SG2014010276A (en) | 2011-08-18 | 2014-03-28 | Nestec Sa | Compositions and methods for detecting allelic variants |
| JP2013081450A (ja) | 2011-09-27 | 2013-05-09 | Arkray Inc | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用試薬キット |
| US11261494B2 (en) * | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
| EP2711432A1 (en) * | 2012-09-21 | 2014-03-26 | Genomica S.A.U. | Method for detection of BRAF and PI3K mutations |
| EP3666903B1 (en) * | 2013-08-12 | 2025-12-31 | Bio-Rad Laboratories, Inc. | AMPLIFICATION REPORTER GENE CONTAINING OLIGOMERS WITH BASIC PAIRINGS |
-
2015
- 2015-07-28 PT PT157537457T patent/PT3198026T/pt unknown
- 2015-07-28 CN CN201580052321.9A patent/CN106715723B/zh active Active
- 2015-07-28 RS RS20191668A patent/RS59710B1/sr unknown
- 2015-07-28 HU HUE15753745A patent/HUE047958T2/hu unknown
- 2015-07-28 WO PCT/GR2015/000036 patent/WO2016020710A1/en not_active Ceased
- 2015-07-28 HR HRP20192353TT patent/HRP20192353T1/hr unknown
- 2015-07-28 PL PL15753745T patent/PL3198026T3/pl unknown
- 2015-07-28 US US15/501,457 patent/US11279979B2/en active Active
- 2015-07-28 DK DK15753745.7T patent/DK3198026T3/da active
- 2015-07-28 CA CA2957396A patent/CA2957396C/en active Active
- 2015-07-28 ES ES15753745T patent/ES2764423T3/es active Active
- 2015-07-28 EP EP15753745.7A patent/EP3198026B1/en active Active
- 2015-07-28 SI SI201531052T patent/SI3198026T1/sl unknown
- 2015-07-28 JP JP2017526770A patent/JP6770957B2/ja active Active
- 2015-07-28 LT LTEP15753745.7T patent/LT3198026T/lt unknown
- 2015-07-28 SM SM20200005T patent/SMT202000005T1/it unknown
-
2017
- 2017-02-01 IL IL250392A patent/IL250392B/en active IP Right Grant
-
2019
- 2019-12-30 CY CY20191101363T patent/CY1122647T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3198026A1 (en) | 2017-08-02 |
| EP3198026B1 (en) | 2019-10-09 |
| JP6770957B2 (ja) | 2020-10-21 |
| SMT202000005T1 (it) | 2020-03-13 |
| US11279979B2 (en) | 2022-03-22 |
| PL3198026T3 (pl) | 2020-05-18 |
| IL250392B (en) | 2020-03-31 |
| ES2764423T3 (es) | 2020-06-03 |
| LT3198026T (lt) | 2020-01-27 |
| CN106715723A (zh) | 2017-05-24 |
| HRP20192353T1 (hr) | 2020-03-20 |
| CN106715723B (zh) | 2021-03-30 |
| US20170233821A1 (en) | 2017-08-17 |
| DK3198026T3 (da) | 2020-01-20 |
| CA2957396C (en) | 2021-03-09 |
| WO2016020710A1 (en) | 2016-02-11 |
| JP2017523810A (ja) | 2017-08-24 |
| HUE047958T2 (hu) | 2020-05-28 |
| SI3198026T1 (sl) | 2020-02-28 |
| CA2957396A1 (en) | 2016-02-11 |
| RS59710B1 (sr) | 2020-01-31 |
| PT3198026T (pt) | 2020-01-16 |
| IL250392A0 (en) | 2017-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122647T1 (el) | Μεθοδος ανιχνευσης των pik3ca μεταλλαξεων σε ενα δειγμα | |
| Tiacci et al. | Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation | |
| Stadler et al. | Current and future clinical applications of ctDNA in immuno-oncology | |
| Wick et al. | MGMT testing—the challenges for biomarker-based glioma treatment | |
| Ishii et al. | Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples | |
| Mwenifumbo et al. | Cancer genome-sequencing study design | |
| Mishra | MicroRNAs as promising biomarkers in cancer diagnostics | |
| Sun et al. | Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer | |
| Vaughn et al. | Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer | |
| Salipante et al. | Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing | |
| WO2013006443A3 (en) | Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma | |
| Spans et al. | Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1 | |
| Kaehler et al. | MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells | |
| Seccia et al. | Somatic mutations in the KCNJ5 gene raise the lateralization index: implications for the diagnosis of primary aldosteronism by adrenal vein sampling | |
| Berenstein et al. | Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia | |
| Hummelink et al. | Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions | |
| Shitara et al. | Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients | |
| Zeng et al. | Detection of PIK3CA mutations in plasma DNA of colorectal cancer patients by an ultra-sensitive PNA-mediated PCR | |
| Palmirotta et al. | Mutational analysis of gastrointestinal stromal tumors (GISTs): procedural approach for diagnostic purposes | |
| Biran et al. | Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques | |
| Cetinkunar et al. | The effect of polymorphism in DNA repair genes RAD51 and XRCC2 in colorectal cancer in Turkish population | |
| Balistreri et al. | Are the leukocyte telomere length attrition and telomerase activity alteration potential predictor biomarkers for sporadic TAA in aged individuals? | |
| Gao et al. | Microdroplet digital PCR: detection and quantitation of biomarkers in archived tissue and serial plasma samples in patients with lung cancer | |
| Walsh et al. | A cautionary lesson on the use of targeted methods for EGFR mutation analysis: a case report | |
| Figg et al. | Pharmacologic biomarkers in the development of stratified cancer medicine |